Patents Assigned to Amgen
  • Use of the human interferon consensus gene for gene therapy
    Patent number: 5831062
    Abstract: The present invention relates generally to a human interferon consensus gene useful for expression in eucaryotic systems and gene therapy. In particular, the present invention relates to treatment of cancer and cell proliferation disorders through use of viral vectors to deliver and express the human interferon consensus gene in the cells and/or tumors of a patient.
    Type: Grant
    Filed: May 8, 1997
    Date of Patent: November 3, 1998
    Assignee: Amgen Inc.
    Inventors: Milton W. Taylor, Lawrence M. Blatt
  • N-terminally chemically modified protein compositions and methods
    Patent number: 5824784
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Olaf B. Kinstler, Nancy E. Gabriel, Christine E. Farrar, Randolph B. DePrince
  • Chemically-modified G-CSF
    Patent number: 5824778
    Abstract: The present invention provides a chemically-modified protein prepared by binding polyethylene glycol to a polypeptide characterized by being the product of expression by a host cell of an exogenous DNA sequence and substantially having the following amino acid sequence: ##STR1## The chemically-modified protein according to the present invention has a much longer lasting neutrophil-increasing activity than that of the intact human G-CSF, enabling fewer numbers of administration with a lower dose.
    Type: Grant
    Filed: November 30, 1992
    Date of Patent: October 20, 1998
    Assignee: Kirin-Amgen, Inc.
    Inventors: Rika Ishikawa, Yuji Okada, Makoto Kakitani
  • Eck receptor ligands
    Patent number: 5824303
    Abstract: Ligands which bind to the eck receptor are disclosed. More particularly, polypeptides which bind specifically to the eck receptor (eck receptor binding proteins or EBPs) and DNA sequences encoding said polypeptides are disclosed. Methods of treatment using eck receptor ligands and soluble eck receptor and disclosed, as are pharmaceutical compositions containing same. A rapid and sensitive method for the detection of receptor binding activity in crude samples is provided.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, William J. Boyle, Gary M. Fox, Andrew A. Welcher, Ella Magal, Richard A. Lindberg, Vann P. Parker
  • Therapeutic uses of keratinocyte growth factor
    Patent number: 5824643
    Abstract: Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 20, 1998
    Assignee: Amgen Inc.
    Inventors: Glenn Francis Pierce, Regina Mae Housley, Charles Frederick Morris
  • Neurogene
    Patent number: 5817784
    Abstract: Disclosed are DNA and amino acid sequences for a novel polypeptide termed Neuritin which is expressed primarily in selected regions of the brain.
    Type: Grant
    Filed: August 9, 1996
    Date of Patent: October 6, 1998
    Assignees: Amgen Inc., Yeda Research and Development Co., Ltd.
    Inventors: Lars Eyde Theill, Gregory Scott Naeve, Yoav Citri, deceased
  • Therapeutic uses of keratinocyte growth factor
    Patent number: 5814605
    Abstract: Based on extensive in vivo studies in animals, it has now been discovered that KGF stimulates proliferation, growth and differentiation in various cells of epithelial tissue, besides keratinocytes. This better understanding of the biological effects of KGF in vivo enables the use of this polypeptide as a therapeutic agent, suitably formulated in a pharmaceutical composition, for the specific treatment of disease states and medical conditions afflicting tissues and organs such as the dermal adnexae, the liver, the lung, and the gastrointestinal tract.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 29, 1998
    Assignee: Amgen Inc.
    Inventors: Glenn Francis Pierce, Regina Mae Housley, Charles Frederick Morris
  • Method for selecting monoclonal antibodies for human G-CSF permitting low-level detection in human fluids
    Patent number: 5798274
    Abstract: The present invention relates to a high affinity monoclonal antibody for human G-CSF and to an enzyme immunoassay using said antibody. Specifically, the practice of the invention permits one skilled in the art to obtain monoclonal antibodies with the characteristics necessary to permit low-level detection of G-CSF in plasma of equal to or less than 0.5 pg/ml in an immunoassay without interference in human fluids.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 25, 1998
    Assignee: Kirin-Amgen, Inc.
    Inventors: Takanori Ichikawa, Tomoaki Kuwaki, Shigeru Matsuki, Katsumi Tachibana
  • Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
    Patent number: 5795569
    Abstract: Disclosed are novel proteins, referred to as megakaryocyte growth and development factors (MGDFs; also generally referred to as Mpl ligands or thrombopoietin, that have a biological activity of stimulating the growth of megakaryocytes and augmenting the differentiation or maturation of megakaryocytes, ultimately to result in the production of platelets. MGDF derivatives comprising MGDF molecules attached to water soluble polymers, such as polyethylene glycol, are also disclosed, along with methods for their preparation. Also disclosed are processes for obtaining the MGDFs in homogeneous form from natural sources and producing them by recombinant genetic engineering techniques from mammals, including humans.
    Type: Grant
    Filed: October 12, 1994
    Date of Patent: August 18, 1998
    Assignee: Amgen Inc.
    Inventors: Timothy D. Bartley, Jakob M. Bogenberger, Robert A. Bosselman, Pamela Hunt, Olaf B. Kinstler, Babru B. Samal
  • Computer apparatus for expressing a three dimensional structure of a G-CSF molecule or analogs thereof
    Patent number: 5790421
    Abstract: The present invention is directed towards a computer apparatus for expressing a three dimensional structure of a G-CSF molecule or analogs thereof.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: August 4, 1998
    Assignee: Amgen Inc.
    Inventor: Timothy David Osslund
  • Methods of inhibiting syp binding to a CTLA-4 receptor
    Patent number: 5786152
    Abstract: Disclosed are methods for identifying a molecule that inhibits SYP activity in a T-cell.
    Type: Grant
    Filed: April 26, 1996
    Date of Patent: July 28, 1998
    Assignee: Amgen Inc.
    Inventors: Luc Edgar Joseph Marengere, David Peter Siderovski, Tak Wah Mak
  • Use of stem cell factor and soluble interleukin-6 receptor to induce the development of hematopoietic stem cells
    Patent number: 5786323
    Abstract: Stem cell factor in combination with gp130 signaling supports proliferation, differentiation and terminal maturation of erythroid cells from normal human hematopoietic stem cells.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: July 28, 1998
    Assignees: Amgen Inc., Tosoh Corporation
    Inventor: Tatsutoshi Nakahata
  • Methods and compositions for determining HER-2/neu expression using monoclonal antibodies
    Patent number: 5783404
    Abstract: Anti-p185.sup.HER-2/neu antibodies which are useful in the detection of HER-2/neu oncogene overexpression in biological samples are described. The antibodies are accurate and reliable in immunocytochemical or immunohistochemical assays of cell and tissue samples. Also described are methods for detecting HER-2/neu oncogene expression in a biological sample using the antibodies of the invention and a diagnostic kit comprising the antibodies. The reagents provide an accurate means of identifying certain cancer patients who have the greatest probability of relapse and/or the least likelihood of survival.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: July 21, 1998
    Assignee: Amgen Inc.
    Inventor: Raymond A. Koski
  • Antibody-induced apoptosis
    Patent number: 5783186
    Abstract: Anti-Her2 antibodies which induce apoptosis in Her2 expressing cells are disclosed. The antibodies are used to "tag" Her2 overexpressing tumors for elimination by the host immune system. Also disclosed are hybridoma cell lines producing the antibodies, methods for treating cancer using the antibodies, and pharmaceutical compositions.
    Type: Grant
    Filed: December 5, 1995
    Date of Patent: July 21, 1998
    Assignee: Amgen Inc.
    Inventors: Tsutomu Arakawa, Yoshiko Kita
  • Purified ciliary neurotrophic factor
    Patent number: 5780600
    Abstract: A ciliary neurotrophic factor (CNTF), particularly sciatic nerve CNTF (SN-CNTF) is claimed. The SN-CNTF described herein is a single protein species and has a specific activity that increased to greater than 25,000-fold from crude extract. Amino acid data for this SN-CNTF is also provided. In addition, methods for using this data for providing SN-CNTF probes and for screening cDNA and genomic libraries are also provided. Recombinant-DNA methods for the production of SN-CNTF are described. Nucleic acid sequences encoding rabbit and human CNTF are provided. A recombinant expression system is provided for producing biologically active CNTF.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: July 14, 1998
    Assignee: Amgen Inc.
    Inventors: Franklin D. Collins, Leu-Fen Lin, Drzislav Mismer, Christine Ko
  • DNA encoding pertussis toxin muteins
    Patent number: 5773600
    Abstract: The development of subunits and subunit analogs of the Bordetella exotoxin by recombinant DNA techniques provides vaccine products that retain their biological activity, are highly immunogenic, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits can result in products that retain immunogenicity, yet are free of enzymatic activity associated with toxin of reactogenicity.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: June 30, 1998
    Assignee: Amgen Inc.
    Inventor: Walter Neal Burnette, III
  • Modified cholera toxin based on mutagenized subunit A
    Patent number: 5770203
    Abstract: The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: June 23, 1998
    Assignees: Amgen Inc., University of Southern California
    Inventors: W. Neal Burnette, Harvey R. Kaslow
  • BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
    Patent number: 5770577
    Abstract: Derivatives of the neurotrophic factors BDNF and NT-3 have been prepared by attachment of these polypeptides to a water soluble polymer, for instance, polyethylene glycol.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: June 23, 1998
    Assignee: Amgen Inc.
    Inventors: Olaf Boris Kinstler, Qiao Yan
  • Anti-inflammatory CD14 peptides
    Patent number: 5766593
    Abstract: The invention relates to anti-inflammatory peptides that are based on peptide regions 7-10, 11-14, and 57-64 of CD14.
    Type: Grant
    Filed: December 30, 1994
    Date of Patent: June 16, 1998
    Assignee: Amgen Inc.
    Inventors: Henri S. Lichenstein, Samuel D. Wright, Linda O. Narhi, Shao-Chieh Juan
  • Genes encoding art, an agouti-related transcript
    Patent number: 5766877
    Abstract: Disclosed is a novel gene termed ART which is expressed primarily in selected regions of the brain, as well as adrenal and lung tissues. Polypeptides encoded by ART are also disclosed, as are methods for preparing ART DNA and amino acid sequences.
    Type: Grant
    Filed: November 27, 1996
    Date of Patent: June 16, 1998
    Assignee: Amgen Inc.
    Inventors: Kevin Lee Stark, Roland Luethy